By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Why New Standards Are Needed for Faster Cancer Drug Approvals
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Public Health > Why New Standards Are Needed for Faster Cancer Drug Approvals
Policy & LawPublic Health

Why New Standards Are Needed for Faster Cancer Drug Approvals

Andrew Schorr
Andrew Schorr
Share
4 Min Read
SHARE

Several years ago I attended an FDA Oncology Drug Advisory Committee (ODAC) hearing. What the medical experts and the FDA regulators wanted to know most was did a proposed new cancer medicine help people live longer? Not better, just longer.

Several years ago I attended an FDA Oncology Drug Advisory Committee (ODAC) hearing. What the medical experts and the FDA regulators wanted to know most was did a proposed new cancer medicine help people live longer? Not better, just longer. The CLL (chronic lymphocytic leukemia) drug in question that day was not recommended for approval because they never could show a “survival advantage.” I think the small biotech that made the drug ended up being closed down. Fortunately, the FDA has approved some other cancer drugs since then where they’ve helped people live better. I take one, Jakafi for myelofibrosis, which greatly reduces symptoms but there’s no clear data yet that people live longer because of it. So thanks to the FDA for becoming more enlightened. But now there’s a need to move still further ahead.

In some cancer conditions people are living for many years with cancer before they eventually succumb. Biochemically recurrent prostate cancer can be like that. There’s evidence the cancer has spread but it’s not obvious where. Another case is in CLL where people with less aggressive subtypes may have had treatment but then be in remission for several years. So here’s the regulatory problem: if people are going to live several or many years with a cancer, how can you early on a measure the effectiveness of a proposed new drug that might help them live longer? In prostate cancer and CLL, to name two examples, that’s the dilemma. There may be a “survival advantage,” for example for one of these promising new “small molecule” pills now in trials, or even a new drug that’s been approved, as in prostate cancer. But you need a test the FDA and other regulatory bodies will accept as a “surrogate” for how long someone lives.

In an interview with Dr. Celestia Higano, a prostate cancer expert, she tells me about just that. And in another interview, with Dr. Peter Hillmen, a CLL expert, he said he is going before the FDA to ask that sensitive tests for MRD (minimal residual disease) be acceptable measures. The idea is new tests, or ones that should be developed, can be an acceptable measure of whether a potential new drug will extend life.

More Read

Medigap Healthcare Plan 101: What To Know About Enrolling In 2020
5 Things You Need to Do to Become a Better Nurse
Keep Refreshments Ready for Your Night Shift at the Hospital
The ABCs of CCJR
Avoid These Dangerous Healthcare Misconceptions as a Millennial Business Owner

My view is the FDA, and other agencies around the world, should work collaboratively with industry and scientists to expeditiously assess if a potential new drug is worth approval. If new tests can speed things up then let’s agree on them and use them.

As some cancers are now becoming more like chronic conditions where you live with them rather than dying fairly quickly from them, we need a new system to measure how lasting “chronic” is.

TAGGED:cancerdrug approvalFDA
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

uv protection in winter
Winter Sun Safety: Why UV Protection Matters Year-Round
Health
October 29, 2025
Nurse Scheduling Software
Evaluating 7 Best Nurse Scheduling Software
Nursing Technology
October 28, 2025
contamination
Batch Failures And The Hidden Costs Of Contamination
Health Infographics
October 21, 2025
Medication Management For Seniors
Simplifying Medication Management For Seniors
Infographics Senior Care
October 21, 2025

You Might also Like

Complex Systems, Part II

November 9, 2011
Psychiatrists are now working online
Global HealthcareHealth ReformMental HealthPolicy & LawPublic Health

Psychiatrists Now Working Online: How the Mental Healthcare Industry Is Evolving

December 12, 2021

Drug Cos. Using REMS to Delay Generic Competition

June 18, 2012

FDA Gives Approval for Lap-Band Use With Less Obese Patients

February 17, 2011
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?